# Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines

> **NCT02236312** · PHASE2 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 359 (actual)

## Conditions studied

- Glabellar Frown Lines

## Interventions

- **DRUG:** Botulinum Toxin Type A
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02236312
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2014-11
- **Final completion:** 2015-05
- **Target enrollment:** 359 (ACTUAL)
- **Last updated:** 2022-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02236312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02236312, "Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02236312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*